Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Other Non-Current Liabilities (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Other Non-Current Liabilities for 7 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 426.26% to $6.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2025, up 426.26% year-over-year, with the annual reading at $6.0 million for FY2025, 426.26% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $6.0 million at Beam Therapeutics, down from $6.7 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $37.6 million in Q2 2021, with the low at $173000.0 in Q1 2023.
  • Average Other Non-Current Liabilities over 5 years is $8.1 million, with a median of $1.1 million recorded in 2024.
  • The sharpest move saw Other Non-Current Liabilities skyrocketed 9150.99% in 2021, then tumbled 99.44% in 2023.
  • Over 5 years, Other Non-Current Liabilities stood at $31.4 million in 2021, then plummeted by 95.61% to $1.4 million in 2022, then tumbled by 78.37% to $298000.0 in 2023, then surged by 279.53% to $1.1 million in 2024, then soared by 426.26% to $6.0 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $6.0 million, $6.7 million, and $357000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.